<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT</h2>
    <div class="badge">2025-09-15T13:09:26+00:00</div>
    <ul>
      <li>For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million net loss in Q2 2024.</li>
<li>R&amp;D expenses were $34.7 million, compared to $14.9 million a year earlier, and G&amp;A expenses were $10.5 million, up from $7.8 million in Q2 2024.</li>
<li>On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target.</li>
<li>The company also announced that it received a $10 million milestone payment from Merck after the first patient was dosed in a lead collaboration program.</li>
<li>(NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.</li>
<li>READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.</li>
<li>Both JANX007 and JANX008 are currently enrolling patients in their respective Phase 1 clinical trials.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT\n• For Q2 2025, Janux reported a net loss of $33.9 million, which is an increase from the $6.0 million net loss in Q2 2024.\n• R&amp;D expenses were $34.7 million, compared to $14.9 million a year earlier, and G&amp;A expenses were $10.5 million, up from $7.8 million in Q2 2024.\n• On September 10, Truist initiated coverage of Janux Therapeutics with a Buy rating and $100 price target.\n• The company also announced that it received a $10 million milestone payment from Merck after the first patient was dosed in a lead collaboration program.\n• (NASDAQ:JANX) is one of the best up and coming stocks with huge upside potential.\n• READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.\n• Both JANX007 and JANX008 are currently enrolling patients in their respective Phase 1 clinical trials." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/truist-initiates-coverage-janux-therapeutics-130926769.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>